A high resolution gas chromatographic/mass spectrometric method for the determination of N‐0923 in human and monkey plasma

A method that combines gas chromatography and mass spectrometry (GC/MS) for the determination of N‐0923 in human and monkey plasma is detailed. This novel drug holds promise for the treatment of Parkinson's disease. Clinical use of N‐0923 will result both in low peak plasma concentrations and in a short half‐life; consequently, a highly sensitive method will be required. Previous methods using high‐performance liquid chromatography with electrochemical detection have given reliable data in high dose studies in animals to 0.3–1.0 ng/mL in plasma but are not considered adequate for studies at clinical levels in humans. The data in this paper will show that GC/MS can offer a new direction in the determination of N‐0923 in human and monkey samples, with reliable data to 25 pg/mL in plasma. This method is presented as a novel approach to the determination of N‐0923, and as a starting point for further development.